ADVERTISEMENT
2 /3 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Business

Novartis and Mirati partner on KRas inhibitor

by Ryan Cross
July 12, 2019 | APPEARED IN VOLUME 97, ISSUE 28

 

Drug companies have long considered KRas, a protein implicated in a large number of cancers, to be undruggable. But that’s starting to change as firms like Amgen, Mirati Therapeutics, and Revolution Medicines line up with new compounds that inhibit a specific mutant form of the protein called KRas G12C. In a nonexclusive partnership with Novartis, Mirati will test its KRas inhibitor in combination with Novartis’s experimental inhibitor of another protein, called SHP2, which is involved in the Ras pathway in cells. Separately, Revolution is developing its own inhibitors of KRas G12C and SHP2.

X

Article:

This article has been sent to the following recipient:

Leave A Comment

*Required to comment